GlassScriptPhysician profile
Rami Manochakian
NPI 1619112034
$45,033.86
in general payments reported to CMS, 2019-2025
12 companies · $5,503 in 2025
The $5,503 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,112 · 2021: $1,010 · 2022: $52.17 · 2023: $3,910 · 2024: $13K · 2025: $5,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Honoraria: $2,600 · Travel and Lodging: $823 · Food and Beverage: $816 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,442.25 |
| Honoraria | $2,600.00 |
| Travel and Lodging | $822.80 |
| Food and Beverage | $816.25 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,058.53 | 2019-2025 | Tagrisso, Imfinzi |
| Novocure INC. | $8,173.24 | 2019-2024 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $4,097.76 | 2024 | |
| Daiichi Sankyo INC. | $3,953.28 | 2024 | Enhertu |
| Janssen Scientific Affairs, LLC | $3,190.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,757.29 | 2020 | |
| Abbvie INC. | $2,537.50 | 2024 | |
| Amgen INC. | $2,138.52 | 2019-2025 | Imdelltra (Amg757) |
| Foundation Medicine, INC. | $69.13 | 2022-2023 | |
| Array Biopharma INC | $31.68 | 2023 | Xalkori, Lorbrena |
| Janssen Biotech, INC. | $26.93 | 2024 | Rybrevant |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Manochakian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.